This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of PRECAUTIONS

Telmisartan Telmisartan/amlodipine besilate Telmisartan/amlodipine besilate/hydrochlorothiazide Telmisartan/hydrochlorothiazide

September 9, 2025

Therapeutic category

Antihypertensives

Non-proprietary name

Telmisartan

Telmisartan/amlodipine besilate

Telmisartan/amlodipine besilate/hydrochlorothiazide

Telmisartan/hydrochlorothiazide

Safety measure

PRECAUTIONS should be revised.

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revised language is underlined.

Current	Revision
11. ADVERSE REACTIONS	11. ADVERSE REACTIONS
11.1 Clinically Significant Adverse Reactions	11.1 Clinically Significant Adverse Reactions
Angioedema	Angioedema
Cases of angioedema with swelling of the face, lip, pharynx/larynx,	Cases of angioedema with swelling of the face, lip, pharynx/larynx,
tongue, etc. have been reported, resulting in dyspnoea due to	tongue, etc. have been reported, resulting in dyspnoea due to
laryngeal oedema, etc.	laryngeal oedema, etc. Of note, intestinal angioedema accompanied
	by abdominal pain, queasy, vomiting, diarrhoea, etc. may occur.